- Conditions
- Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Interventions
- Chest Radiography, Computed Tomography, Follow-Up, Imaging Technique, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 7,390
matching trials from the live ClinicalTrials.gov search.
- Conditions
- X-linked Severe Combined Immunodeficiency (XSCID)
- Interventions
- Campath, Palifermin, Busulfan, Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 50 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Solid Tumors
- Interventions
- ON 01910.Na and irinotecan, ON 01910.Na and oxaliplatin
- Drug
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Advanced/Metastatic Tumors
- Interventions
- Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Etoposide, Capecitabine, Bevacizumab, Pembrolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 5 more
- Conditions
- Advanced Solid Tumor
- Interventions
- RP-3500 (camonsertib), Talazoparib, Gemcitabine Injection
- Drug
- Lead sponsor
- Repare Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Boston, Massachusetts • New York, New York + 4 more
- Conditions
- Gynecologic Cancer
- Interventions
- Digital Health Mobile App, Virtual Support Group, Health Coaching, FitBit, Handouts
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Rina-S
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 21
- States / cities
- Fountain Valley, California • Irvine, California • San Diego, California + 17 more
- Conditions
- Cryopyrin Associated Periodic Syndrome
- Interventions
- VTX2735
- Drug
- Lead sponsor
- Zomagen Biosciences Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- San Diego, California • Columbus, Georgia
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- dasatinib, lapatinib ditosylate, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
- Interventions
- Elimusertib (BAY1895344)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 14
- States / cities
- Duarte, California • Tampa, Florida • Atlanta, Georgia + 10 more
- Conditions
- Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
- Interventions
- Nivolumab, Relatlimab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Maraviroc
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2023
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Orange, California • Wilmington, Delaware + 10 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Durvalumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Gainesville, Georgia • Knoxville, Tennessee
- Conditions
- Sarcoma, Liposarcoma
- Interventions
- Palbociclib 200mg, Palbociclib 125mg
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Castration-Resistant Prostate Adenocarcinoma
- Interventions
- CCW702
- Drug
- Lead sponsor
- Calibr, a division of Scripps Research
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- San Diego, California • Baltimore, Maryland • Detroit, Michigan + 2 more
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 62
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Dalutrafusp alfa, mFOLFOX6 Regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • Dallas, Texas + 1 more
- Conditions
- Advanced Cancer, Advanced Solid Tumors
- Interventions
- CP-751,871, Sunitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Santa Monica, California • Philadelphia, Pennsylvania + 1 more
- Conditions
- Bladder Cancer
- Interventions
- Durvalumab, Tremelimumab, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Terence Friedlander, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Smoking
- Interventions
- Peer telephone cessation counseling
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Bladder Cancer
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 35 more
- Conditions
- COVID-19, SARS-CoV-2 Infection
- Interventions
- CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032), Placebo
- Biological
- Lead sponsor
- Kara Chew
- Other
- Eligibility
- 40 Years to 64 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Francisco, California
- Conditions
- HIV Infection
- Interventions
- Emtricitabine/tenofovir disoproxil fumarate, Ritonavir, Atazanavir, Raltegravir, Darunavir
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 26
- States / cities
- Los Angeles, California • San Francisco, California • Torrance, California + 18 more
- Conditions
- Kidney Transplant Rejection
- Interventions
- Diagnostic Test: TruGraf® Testing
- Diagnostic Test
- Lead sponsor
- Transplant Genomics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- La Jolla, California